tetano
Editor, Senior Moderator
Diabetes Metab Res Rev
. 2022 Dec 23;e3606.
doi: 10.1002/dmrr.3606. Online ahead of print.
Dyslipidemia and SARS-CoV-2 spike antibody titers after the second and third doses of the BNT162b2 vaccine among healthcare workers in Japan
Zobida Islam[SUP] 1 [/SUP], Shohei Yamamoto[SUP] 1 [/SUP], Tetsuya Mizoue[SUP] 1 [/SUP], Yusuke Oshiro[SUP] 2 [/SUP], Natsumi Inamura[SUP] 2 [/SUP], Maki Konishi[SUP] 1 [/SUP], Mitsuru Ozeki[SUP] 2 [/SUP], Wataru Sugiura[SUP] 3 [/SUP], Norio Ohmagari[SUP] 4 [/SUP]
Affiliations
Abstract
Objective: This study aimed to examine the sex-associated differences in the relationship between dyslipidemia and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike immunoglobulin (Ig)G antibodies among BNT162b2 vaccine recipients.
Methods: Participants were staff members (aged 21-75 years) of a medical and research institution who underwent an anti-SARS-CoV-2 spike IgG antibody test after the second (n=1,872) and third doses (n=1,075) of the BNT162b2 vaccine. Dyslipidemia was defined as triglyceride level ≥150 mg/dL, high-density lipoprotein-cholesterol level <40 mg/dL, low-density lipoprotein-cholesterol level ≥140 mg/dL, or lipid-lowering medication use. Multivariable linear regression was used to calculate the ratio of means for SARS-CoV-2 spike IgG titer according to dyslipidemia status.
Results: The prevalence of dyslipidemia was 38.0% in men and 19.6% in women. The relationship between dyslipidemia and SARS-CoV-2 spike IgG titers after the second dose differed markedly by sex (P for interaction < 0.001). In men, dyslipidemia was associated with significantly lower IgG titers: ratio of means [95% confidence interval (CI)] was 0.82 (0.72-0.93). However, this association disappeared after the third dose (0.96 [0.78-1.18]). Of dyslipidemia components, hypertriglyceridemia was inversely associated with SARS-CoV-2 spike IgG antibody titer after both the second and third doses [ratio of means: 0.82 (0.70-0.95) and 0.73 (0.56-0.95), respectively]. In women, IgG titers did not differ according to dyslipidemia or hypertriglyceridemia status after either dose.
Conclusion: These results suggest a detrimental role of hypertriglyceridemia in the humoral immune response to the BNT162b2 vaccine for COVID-19 in men but not in women. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; SARS-CoV-2; dyslipidemia; hypertriglyceridemia; immunogenicity; vaccine.
. 2022 Dec 23;e3606.
doi: 10.1002/dmrr.3606. Online ahead of print.
Dyslipidemia and SARS-CoV-2 spike antibody titers after the second and third doses of the BNT162b2 vaccine among healthcare workers in Japan
Zobida Islam[SUP] 1 [/SUP], Shohei Yamamoto[SUP] 1 [/SUP], Tetsuya Mizoue[SUP] 1 [/SUP], Yusuke Oshiro[SUP] 2 [/SUP], Natsumi Inamura[SUP] 2 [/SUP], Maki Konishi[SUP] 1 [/SUP], Mitsuru Ozeki[SUP] 2 [/SUP], Wataru Sugiura[SUP] 3 [/SUP], Norio Ohmagari[SUP] 4 [/SUP]
Affiliations
- PMID: 36562447
- DOI: 10.1002/dmrr.3606
Abstract
Objective: This study aimed to examine the sex-associated differences in the relationship between dyslipidemia and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike immunoglobulin (Ig)G antibodies among BNT162b2 vaccine recipients.
Methods: Participants were staff members (aged 21-75 years) of a medical and research institution who underwent an anti-SARS-CoV-2 spike IgG antibody test after the second (n=1,872) and third doses (n=1,075) of the BNT162b2 vaccine. Dyslipidemia was defined as triglyceride level ≥150 mg/dL, high-density lipoprotein-cholesterol level <40 mg/dL, low-density lipoprotein-cholesterol level ≥140 mg/dL, or lipid-lowering medication use. Multivariable linear regression was used to calculate the ratio of means for SARS-CoV-2 spike IgG titer according to dyslipidemia status.
Results: The prevalence of dyslipidemia was 38.0% in men and 19.6% in women. The relationship between dyslipidemia and SARS-CoV-2 spike IgG titers after the second dose differed markedly by sex (P for interaction < 0.001). In men, dyslipidemia was associated with significantly lower IgG titers: ratio of means [95% confidence interval (CI)] was 0.82 (0.72-0.93). However, this association disappeared after the third dose (0.96 [0.78-1.18]). Of dyslipidemia components, hypertriglyceridemia was inversely associated with SARS-CoV-2 spike IgG antibody titer after both the second and third doses [ratio of means: 0.82 (0.70-0.95) and 0.73 (0.56-0.95), respectively]. In women, IgG titers did not differ according to dyslipidemia or hypertriglyceridemia status after either dose.
Conclusion: These results suggest a detrimental role of hypertriglyceridemia in the humoral immune response to the BNT162b2 vaccine for COVID-19 in men but not in women. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; SARS-CoV-2; dyslipidemia; hypertriglyceridemia; immunogenicity; vaccine.